Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

• Main Authors: Amit A. Joharapurkar (Author), Vishal J. Patel (Author), Samadhan G. Kshirsagar (Author), Maulik S. Patel (Author), Hardikkumar H. Savsani (Author), Chetan Kajavadara (Author), Darshan Valani (Author), Mukul R. Jain (Author)
• Format: Book
• Published: Elsevier, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Many anemic chronic kidney disease (CKD) patients are refractory to erythropoietin (EPO) effects due to inflammation, deranged iron utilization, and generation of EPO antibodies. This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on...